Types of Cancer We Treat

Melanoma

As one of the first skin cancer treatment programs in New York City, we have long been at the forefront of melanoma research and care. We created the ABCDE screening system—now a standard diagnostic tool—to help identify melanoma at an early stage, when treatment is most effective.

Our dermatologists, dermatopathologists, oncologic surgeons, reconstructive plastic surgeons, medical oncologists, radiation oncologists, and pathologists combine their expertise to customize a treatment plan for you.

Our melanoma surgeons specialize in removing the cancer while preserving appearance and function, and our medical oncologists provide the latest targeted treatments, including genetically engineered injectable therapies.

Meet Our Doctors
Dr. Jeffrey Weber
Melanoma Diagnosis Our Approach to Melanoma Treatment
Diagnosis
Melanoma Diagnosis
Surgery
Melanoma Surgery
Targeted Drugs & Immunotherapy
Melanoma Targeted Drugs and Immunotherapy
Radiation Therapy
Melanoma Radiation Therapy

Related News

NYU Langone Receives Grant for Melanoma Research
Read Story
Blood Test to Measure Effectiveness of Skin Cancer Treatment
Read Story
Treatment Options for Later-Stage Melanoma
Read Story
Investigators Develop Novel Blood Tests for Tumor DNA
Read Story
How a Mentor–Mentee Team Found a New Understanding of Cancer
Read Story
Cancer Experts Share Updates in Immunology Advances
Read Story
Expert Discusses Taking Care of Your Skin This Summer
Read Story
Immunotherapy Provides New Options for Advanced Cancers
Read Story
Doctors Define Surgical Margins for Removing Skin Moles
Read Story
New Immunotherapy Drug More Effective in Treating Melanoma
Read Story
Viagra-Like Drugs Not Linked to Skin Cancer, Study Finds
Read Story
Screening Guidelines for Skin Cancer & Melanoma, Explained
Read Story

Clinical Trials and Research Studies

Phase 3

A Multicenter Open label Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial (MK3475-587)

Learn More

Phase 2

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma

Learn More

Phase 1

A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Solid Tumors and Lymphomas

Learn More

Phase 2

A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (mRNA-4157-P201)

Learn More
View All Related Clinical Trials (20)